跳至主要内容
临床试验/NCT04542044
NCT04542044已完成不适用

Evaluation of the Safety and Outcomes of Outpatient Management With Mild to Moderate COVID-19 Pneumonia (PneumoCoV-Ambu)

University Hospital, Geneva1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2020年4月2日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
40
试验地点
1
主要终点
Secondary hospitalization(s) or death COVID-19 related

研究概览

简要总结

The purpose of this study is to evaluate the strategy of investigators for outpatients SARS-CoV-2 moderate pneumonia management in terms of efficacy and patient safety. The investigators ultimate goal is to validate first wave management strategy in order to support the investigators future approach in the event of a second wave, and spare the hospital resources by safely keeping at home as many patients as possible.

详细描述

The investigators focused on participants consulting in the emergency department at the HUG who remained in an outpatient setting, with pneumonia and moderate illness, defined by individuals who have evidence of lower respiratory disease by clinical assessment or imaging and a saturation of oxygen (SaO2) >93% on room air and no other hospitalization criteria (CURB 65 score below 2points).

For patients' follow-up, the investigators have created an aftercare ambulatory unit, open 5/7 days. The investigators were able to conduct 64 consultations between April 2 and May 5, 2020. Every participant had suspected or confirmed SARS-CoV-2 pulmonary tract infection.

The follow-up data was entered into DPI (patient's medical record at HUG) on a specific consultation form. Patients followed in the investigators consultation were contacted between 30 and 60 days after diagnosis by the Covicare team. The Covicare team is call-center composed of medical students and primary care physicians who remotely followed patients with COVID-19 by calling them by phone or telemedicine every day or every other day depending on patients' needs and health status. The investigators will export data from RedCap concerning post-hospitalization, satisfaction survey on our care and oral consent for use of data (ARGOS study CCER number 2020-01273).

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 99 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All persons with suspected or confirmed SARS-CoV-2 pneumonia who consulted in the emergency department of the HUG without criteria for hospitalization4 (Pneumonia with CURB-65 >= 2 or new O2 dependency or increased O2 requirements or sustained respiratory rate≥20 min or decompensated comorbidity or major alteration of the general state) and who have been scheduled for outpatient follow-up in HUG.

排除标准

  • Patients with hospitalization criteria
  • Refusal to consent documentation found in the computerized patient record or oral refusal consent during follow up call.

结局指标

主要结局

Secondary hospitalization(s) or death COVID-19 related

时间窗: 30 to 60 days from diagnosis

次要结局

  • severity of COVID-19 disease(30 to 60 days from diagnosis)
  • patient satisfaction with management strategies(30 to 60 days from diagnosis)
  • Saved costs(30 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Chevallier-Lugon Chloé

Chief resident

University Hospital, Geneva

研究点 (1)

Loading locations...

相似试验

Evaluation of the Safety and Outcomes of Outpatient... | 临床试验